Distributor interest now open
Line up early access to ORTIV needle-free glucose monitoring
ORTIV is a Korean blood glucose monitoring device from MVITRO. It combines laser blood sampling and glucose measurement in one compact handheld device, helping reduce the pain, fear, and disposable-needle waste associated with traditional finger-prick testing.
Nalin MedTech is collecting qualified distributor and procurement interest ahead of European commercial availability. This helps prioritise demonstrations, documentation, and rollout conversations.
Watch ORTIV in action
See the ORTIV laser blood sampling workflow and MVITRO device interface in this manufacturer overview video.
In plain English
Traditional glucose meters still matter, especially in pharmacies, clinics, chronic-care programmes, and home monitoring. ORTIV keeps the familiar blood glucose meter workflow, but replaces the needle-prick sampling step with a laser-based approach.
For distributors and healthcare buyers, the opportunity is a more approachable monitoring experience for repeat users, with less needle fear and a lower consumable needle burden.
Why ORTIV is different
- Painful needle prick
- Multiple parts
- Needle reuse concerns
- Disposable lancet waste
- Testing anxiety for repeat users
- Laser-based blood sampling
- Sampling and monitoring in one device
- Improved comfort for repeat users
- Reduced consumable needle waste
- Connected data for follow-up care
Key specifications
125 g
ORTIV is designed as a compact handheld blood glucose monitor. Manufacturer materials describe approximately 200 measurements per full charge, USB-C charging, and laser output of 50-150 mJ.
| Product | ORTIV |
| Item | Blood glucose meter |
| Device type | ORTIV-WH / ORTIV-BL |
| Charging power | 5V 2A, USB-C |
| Battery | 3.7V, 1200 mAh |
| Weight | 125 g |
| Laser output | 50-150 mJ |
| Size | 68.0 x 103.0 x 30.0 mm |
| Operating temperature | 10-40 C |
| Operating humidity | Under 90% |
| Measurements per charge | About 200 per full battery charge |
Who should look at ORTIV?
Manufacturer and regulatory status
ORTIV is manufactured by MVITRO Co., Ltd., a Seoul-based Korean medical-device company focused on home-use and laser-based pre-diagnostic devices. Manufacturer materials reference US FDA 510(k) clearance for the ORTIV laser lancing instrument and ongoing EU CE marking work.
EU availability is subject to CE marking under the EU In Vitro Diagnostic Regulation before placement on the EU/EEA market.
Common questions
What is ORTIV?
ORTIV is a Korean blood glucose monitoring device from MVITRO that combines laser blood sampling and glucose measurement in one handheld device.
Is ORTIV needle-free?
ORTIV uses laser blood sampling instead of a conventional disposable lancet needle, reducing the discomfort and fear associated with traditional finger-prick testing.
Does ORTIV connect to an app?
Yes. MVITRO materials describe app integration for automatic data synchronization, real-time glucose upload, trend analysis, and HbA1c estimation.
Can we register early interest?
Yes. Qualified distributors, pharmacy groups, and healthcare buyers can register early interest with Nalin MedTech. This is a commercial enquiry, not a completed sale, and remains subject to regulatory status, territory availability, allocation, and final terms.
Is ORTIV available in Europe?
CE marking under the EU IVDR is in progress. Until CE marking is complete, ORTIV is not available for sale within the EU/EEA.
Regulatory notice. ORTIV is manufactured by MVITRO Co., Ltd. in the Republic of Korea. CE marking under the EU In Vitro Diagnostic Regulation (2017/746) is in progress; ORTIV is not yet available for sale within the EU/EEA. The US FDA 510(k) clearance referenced applies to the laser lancing instrument in the United States only. Early distributor interest is a non-binding commercial enquiry and does not constitute an offer for sale.